Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. News
  7. Summary
    UCB   BE0003739530


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufacturing technology in Gene Therapy

09/07/2021 | 08:51am EDT

DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufacturing technology in Gene Therapy 2021-09-07 / 14:50 The issuer is solely responsible for the content of this announcement.


CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufacturing technology in Gene Therapy . The ELEVECTA(R) Technology produces Stable Producer Cell Lines designed to enable fully scalable,high-performance AAV vector production . Under the agreement, CEVEC grants UCB rights and options to the ELEVECTA(R) Technology for the research,development and manufacturing of AAV gene therapy products

Cologne, Germany, September 07^th, 2021

CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an agreement with UCB S.A. (UCB; Euronext: UCB) on the evaluation and use of CEVEC's proprietary ELEVECTA(R) Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.

According to the agreement, CEVEC grants UCB non-exclusive rights for research and development using ELEVECTA(R) producer cell lines for specific transgenes selected by UCB. The agreement also grants UCB options to obtain licenses for use of the ELEVECTA(R) producer cell lines in commercial manufacturing of potential AAV gene therapy products, and for the internal use of the ELEVECTA(R) Technology at UCB to generate new producer cell lines. Under the terms of the license, CEVEC is eligible for license fees, clinical and regulatory milestone payments, as well as royalties on potential future net sales. Financial details of the agreement were not disclosed.

"We are very pleased to have UCB embarking on the ELEVECTA(R) Technology enabling them to use the platform for scalable, robust and efficient manufacturing of gene therapy vectors," said Dr. Nicole Faust, Chief Executive Officer of CEVEC. "This license agreement represents a further step towards establishing ELEVECTA(R) as the future AAV manufacturing standard. With more and more gene therapies in development, we see an increasing need in the industry for scalable manufacturing technologies to enable production of AAV vectors at large scale." About ELEVECTA(R)

The ELEVECTA(R) Technology is an innovative technology platform developed by CEVEC for the production of AAV gene therapy vectors. The technology is based on stable, helper virus-free producer cell lines which have all functions required for AAV production stably integrated into the genome of a producer cell, including the capsid and the transgene. Unlike other technologies, neither transient transfection nor helper virus is needed for production, enabling low batch-to-batch variations. ELEVECTA(R) is fully compatible with standard processes and methods for purification and analysis. Custom-made producer cell lines can serve as research cell banks or as fully tested cGMP Master Cell Banks for manufacturing of clinical and commercial material. The technology is patent protected by CEVEC and is designed to overcome the limitations of current manufacturing methods. About CEVEC

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company's product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins. With the ELEVECTA(R) Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC's CAP(R) Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, viral vaccines and exosomes. With the CAP-Go(R) Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

For more information, please visit the Company's website.

Follow CEVEC on LinkedIn and Twitter. Contact:

CEVEC Pharmaceuticals GmbH MC Services AG 
Dr. Ulrich Kettling        Dr. Solveigh Mähler 
Chief Business Officer     Public Relations 
P.: +49 221 460 208 00     P.: +49 211 529 252 19 
E.: info@cevec.com         E.: solveigh.maehler@mc-services.eu 


2021-09-07 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


1231236 2021-09-07

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1231236&application_name=news

(END) Dow Jones Newswires

September 07, 2021 08:50 ET (12:50 GMT)

All news about UCB
10/22UCB : Disposals of own shares
10/20UCB to License Its AI Technology That Improves Identification of Osteoporosis to ImageB..
10/20UCB : to license its AI technology that improves identification of …
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
10/18UCB : Disposals of own shares
10/16UCB : Update on U.S. FDA Review of Biologics License Application …
10/16Update on U.S. FDA Review of Biologics License Application for UCB's bimekizumab
10/08UCB : Disposals of own shares
10/07UCB : Partnering with UpskillMe to inspire tomorrow's innovators
More news
Analyst Recommendations on UCB
More recommendations
Sales 2021 5 616 M 6 517 M 6 517 M
Net income 2021 961 M 1 116 M 1 116 M
Net Debt 2021 809 M 939 M 939 M
P/E ratio 2021 19,2x
Yield 2021 1,28%
Capitalization 18 847 M 21 852 M 21 868 M
EV / Sales 2021 3,50x
EV / Sales 2022 3,56x
Nbr of Employees 7 600
Free-Float 59,1%
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 21
Last Close Price 99,82 €
Average target price 114,00 €
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris L÷w-Friedrich Chief Medical Officer & EVP-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
UCB18.16%21 852
CSL LIMITED4.53%100 969
BIOGEN INC.10.24%40 230